17 May

Prime Nordic has invested in IRLAB Therapeutics AB, a biotech company that develops drugs for the treatment of Parkinson’s disease.  The company considers this a field with a huge industry growth potential.

Prime Nordic believes that IRLAB has a strong management team with a proven track record in the field of life sciences and biotech.  The team is ensembled from members of Nobel Laureate Prof. Arvid Carlsson’s research group from the Department of Pharmacology at Gothenburg University.

Paired with a solid shareholder structure, with Goldman Sachs & Co, Danica Pension and the National Swedish Pension Funds 3 & 4 among the shareholders, IRLAB has the necessary requirements for a Prime Nordic Investment.

The share is listed on the Nasdaq First North Premier Stock Market under the ticker IRLAB.

For more information, press only:

Kevin Shinduke Kevin.Shinduke@primenordic.com

* The email will not be published on the website.